维生素D和依赖胰岛素的糖尿病:临床试验的系统审查
Yuval Dadon1, Lior Hecht Sagie1, Francis B Mimouni2,3
1Ministry of Health, Jerusalem 9101002, Israel.
Nutrients
|April 13, 2024
概括
维生素D补充剂没有强有力的证据表明维护β细胞或改善新发型1型糖尿病 (T1DM) 的血糖控制. 需要进一步的研究,尽管建议在T1DM患者中为骨健康提供足够的维生素D.
科学领域:
- 内分泌学 在内分泌学.
- 儿科 儿科 儿科
- 营养科学 营养科学
背景情况:
- 关于维生素D补充对1型糖尿病 (T1DM) 发病后β细胞保存的影响存在相互矛盾的结果.
- 维生素D在治疗新发型T1DM中的作用需要进一步阐明.
研究的目的:
- 系统地审查随机前性受控试验 (RCT).
- 为了确定改善的维生素D状况是否可以防止T1DM的进展或有助于维护β细胞.
主要方法:
- 按照PRISMA指导方针,在2024年1月18日之前进行系统审查.
- 使用关键词搜索了MEDLINE,Embase和Cochrane数据库:"维生素D"",1型糖尿病"和"儿童".
- 包括11个经过严格选后的RCT;由于异质性而进行的定性分析.
主要成果:
- 没有强有力的证据表明,维生素D补充对新发T1DM的β细胞保存产生持久的益处.
- 维生素D补充剂在受试者中没有显著改善血糖控制.
- 研究设计和结果之间显著的异质性阻止了元分析.
结论:
- 需要更严格和更大规模的研究来最终评估维生素D对贝塔细胞功能和新发型T1DM的血糖控制的影响.
- 由于骨质疏松症的风险,建议新发型T1DM患者服用足够的维生素D水平.
相关概念视频
Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K
Insulin: Dosing Regimen and Adverse Effects
169
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
169
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Oral Hypoglycemic Agents: Biguanides and Glitazones
195
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
195
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Dipeptidyl Peptidase 4 Inhibitors
182
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
182


